At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
250 mg/m2 aldoxorubicin +1 moredrug
Likely dose
250 mg/m2 aldoxorubicinfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide
In Brief
A Phase 2 clinical trial evaluating 250 mg/m2 aldoxorubicin and 350 mg/m2 aldoxorubicin for Glioblastoma. Completed, enrolled 28 participants across 4 sites.
Detailed Summary
This is a pilot study to determine the efficacy and safety of aldoxorubicin in subjects with glioblastoma who have progressed following surgery and prior treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartMar 2014
Primary CompletionDec 2016
TodayJul 2026
First PostedDec 18, 2013
Enrollment StartMar 1, 2014
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.5 years ago
Interventions
250 mg/m2 aldoxorubicindrug
350 mg/m2 aldoxorubicindrug